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Abstract
Objective: Chronic myeloid leukemia (CML) is a rare disease in childhood. While
hematopoietic stem cell transplant (HSCT) was the treatment of choice for CML prior to
2000, the introduction of tyrosine kinase inhibitors (TKIs) changed the management of this
disease. . This population-based analysis was conducted in the province of Ontario, Canada
to gather information on treatment choices and outcomes of childhood CML.
Method: Using a provincial childhood cancer registry and retrospective review of patient
medical records for patients <18 years diagnosed with CML between 1985 and 2018, data
on presenting features, treatment and outcomes was collected from 52 patients.
Results: Patients treated before the introduction of TKIs (<2002) mainly received HSCT and
had an overall survival (OS) of 64% at a median follow up of 6 years. The OS of all patients
treated in the TKI era (≥ 2002) was 90% at a median follow up of 3 years. All three deaths in
the TKI era were related to HSCT complications. Survival of patients who remained on a TKI
was significantly improved compared to those who underwent HSCT post TKI therapy (100%
vs 66%, p = 0.008). TKIs were well tolerated.
Conclusion: Given the increased mortality associated with HSCT in our cohort, further
advances in HSCT may be required to outweigh the benefits of a TKI mono-therapy
approach in the majority of childhood CML patients. We believe HSCT should be considered
in only a limited subset of pediatric patients with CML.
Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative disorder of hematopoietic stem cells
that is rare in children, accounting for 2-3% of pediatric leukemias 1. If untreated, CML
progresses through 3 phases; the chronic phase (CP), the accelerated phase (AP), and the
blast phase (BP); most patients present in the chronic phase. While allogeneic
hematopoietic stem cell transplant (HSCT) was the treatment choice for CML prior to 2000,
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the introduction of imatinib in the early 2000s changed the management of this disease.

Much of what is known about this disease and its therapy is based on studies of adult
patients, with few clinical trials performed in pediatrics. The care of children with CML offers
unique challenges. Compared with adults, children with CML are more likely to present with
AP and BP disease and are less likely to achieve an early favorable molecular response

2,3

.

Studies have suggested that there are differences in the biology of childhood CML, including
variability in BCR-ABL1 breakpoints 4. The safety and efficacy of imatinib in the treatment of
childhood CML has been confirmed in multiple studies 5-7. More recently, initial pediatric data
is now available for second generation TKIs, including dasatinib and nilotinib 8,9. TKI monotherapy is considered standard therapy for those presenting in CP with adequate disease
response. HSCT is now considered only in a subset of children with CML, namely those who
present with, or progress to, blast phase. Potential side effects of TKIs that may be
problematic in children include musculoskeletal events, growth restriction 10 and decreased
bone mineral density 11. Recent adult trials have demonstrated that some patients with
stable CML with a sustained deep molecular response can safely stop TKI therapy without
relapsing 12-14. Data on the safety of ceasing TKI therapy in children with CML is extremely
limited 15.

Permanent eradication of leukemia stem cells by HSCT could be argued as a reasonable
approach to CML therapy 2, given the potential lifetime exposure to TKI therapy at critical
growth periods in childhood, along with the with limited data on long-term side effects and
the biologic differences between childhood and adult CML 2,16. Information is limited
regarding specific treatment choices, disease outcomes and morbidity of the two treatment
strategies in children. Additionally, outcome data after pediatric patients with CML who fail
first line TKI therapy, develop blast phase or are refractory to any TKI treatment, are limited.
This article is protected by copyright. All rights reserved.
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This population cohort examines the outcomes of children with CML treated in the province
of Ontario over a 30+ year period.

Methods
A multicenter retrospective analysis of patients with CML diagnosed between 1985 and 2018
was conducted across five pediatric oncology centers in the province of Ontario, Canada.
Patients were identified through the Pediatric Oncology Group of Ontario Networked
Information System (POGONIS). POGONIS is a population based cancer registry that
collects demographic, disease and treatment details on all pediatric cancer cases diagnosed
and/or treated at one of the five tertiary care centers in Ontario. Additional clinical details
were abstracted from patient medical records to supplement the data available in POGONIS.
Children and adolescents <18 years of age with confirmed BCR-ABL1 transcripts were
included. Phase of disease at diagnosis and response assessment were classified as per
the ELN guidelines 17. Descriptive statistics were used to summarize patient and treatment
characteristics, along with outcomes. Statistical analyses and Kaplan Meier curves were
performed with GraphPad Prism software version 6.03 (GraphPad Software Inc.). Each
participating institution provided IRB approval.
This article is protected by copyright. All rights reserved.
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Results
With a population estimate of 14.7 million in the province of Ontario 18, from 1985 to 2018, 52
children and adolescents diagnosed with CML within the pediatric oncology system in
Ontario were identified. Baseline patient characteristics are presented in table 1. Median age
of patients was 10.5 years (1.8 -18 years). The majority of patients presented in the chronic
phase (88%). The most common symptoms at presentation were bone pain and fatigue
(each occurring in 28% of patients). Seventeen percent of patients were asymptomatic at
diagnosis. Seventy-two percent of patients had splenomegaly on exam at diagnosis. Imatinib
was first incorporated into treatment plans in 2002; this time point is used as a dividing factor
to evaluate patients in the pre and post TKI era. From 1985 to 2002, twenty-two patients did
not receive TKI therapy (figure 1). The majority of these patients (18/22, 82%) received
treatment that included HSCT (matched sibling donor= 11, matched unrelated donor= 4,
haploidentical donor = 2, autologous HSCT = 1). Four patients were unable to receive HSCT
in the pre TKI era because no donor was available. Patients who underwent HSCT in the pre
TKI era presented in CP (n = 14), AP (n = 1), BP (n = 3). Ten of these patients were reported
as having achieved a complete hematologic remission prior to HSCT (56%). The overall
survival for the entire pre-2002 cohort at a median follow up of 6 years was 63.6% (14/22).
Of the eight patients who died, four died without having received a transplant (causes; blast
crisis (n =2), refractory thrombocytopenia leading to massive intracranial hemorrhage (n =
1), one cause of death was unreported (n = 1). Four patients died post HSCT (causes;
progressive disease post HSCT (n = 1), bronchiolitis obliterans organizing pneumonia (n =1),
graft versus host disease and sepsis (n = 1), HSV pneumonia post HSCT (n= 1)).

The “TKI era” cohort consisted of thirty patients. Twenty-three patients were treated with
This article is protected by copyright. All rights reserved.
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imatinib as first line therapy; four patients were treated with dasatinib as first line therapy.
Fifty-two percent of patients that were started on imatinib remained on this TKI at last followup. Elective HSCT was performed upfront without the use of TKI therapy in three patients.
TKIs were used exclusively as first line therapy in all institutions from 2005 onwards (see
table 2). Of those that initially responded to TKI therapy, complete hematologic response
was achieved at a median of 2 months (range 1-4 months). Complete cytogenetic response
was achieved at a median of 7 months (range 1 – 17 months). Major molecular response
was achieved at a median of 8 months (range 1-32 months).

Nine patients treated upfront with TKIs underwent HSCT from 2005-2018. Two of these
patients underwent HSCT electively between 2002-2005, after TKI treatment was initiated.
One patient had BC at diagnosis and underwent HSCT after one month of TKI therapy. Six
of these patients underwent HSCT secondary to poor disease response to TKI therapy
(three patients did not obtain a cytogenetic remission and three patients developed BC on
TKI therapy). TKIs were continued post transplant in four patients for a varied period of time.
Of the nine patients who underwent HSCT after TKI therapy, three patients died (all had
matched unrelated HSCT). All three deaths were related to HSCT complications.

One patient who developed resistance to imatinib was switched to dasatinib and HSCT
deferred secondary to family decision. This patient is still alive and in remission (this was the
only patient for whom HSCT was not performed after initial TKI failure). The overall survival
of all patients treated in the TKI era at a median follow up of three years was 90% (27/30).
Survival of patients who remained on a TKI was significantly improved compared to those
who underwent HSCT post TKI therapy (100% vs 66%, p = 0.008, figure 2). Comparing
outcomes pre and post 2002, survival was similar between those who underwent HSCT after
2002 and all patients pre-2002 (figure 3). In contrast patients treated with TKI alone had
This article is protected by copyright. All rights reserved.
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remarkably better outcomes (figure 3).

TKIs were well tolerated in this cohort. Two patients had side effects from imatinib (GI upset,
joint effusions) and were switched to dasatinib with resolution of symptoms. WHO height
centile changes from time of diagnosis until last follow up were recorded in patients ≤ 12
years to investigate if TKIs caused a change in height velocity in individual patients over
time, compared to HSCT. The change in height velocities over time was averaged for each
group; both groups had a slight decrease in height velocity from diagnosis (approximately
0.5 centile height decrease In both groups). This difference in height velocities between
groups was not significant: HSCT (mean = 0.57 centile height decrease, SD = 0.38), TKI
monotherapy (mean = 0.56 height centile decrease, SD = 0.29), t (13) = 0.02, p = 0.98.

Discussion
This report is based on a population of pediatric patients with CML treated in Canada. This
population-based assessment enabled us to investigate the management of CML across five
pediatric oncology centers, thus giving us a good sense of the real-world management of
this disease, outside of a clinical trial. Our study supports the use of TKI mono-therapy in
childhood CML, given the decreased mortality in those who received and responded to
imatinib. Imatinib was well-tolerated and only discontinued in two patients secondary to
refractory nausea and unexplained joint effusions. Additionally, there was no significant
effect on growth parameters in patients using TKIs, compared to those who received HSCT.

Current recommendations suggest HSCT for children with progression to BP while on a TKI.
For those who progress to AP while on TKI therapy, recent recommendations are to initiate
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treatment with a second generation TKI; HSCT should be postponed as long as no failure to
second line treatment is suspected 19. Likewise, switching to a second generation TKI
followed by monthly monitoring for 3 months is recommended for patients with imatinib
failure, without an identified mutation 19. Our data is in agreement with these
recommendations, given the increased mortality associated with HSCT in this cohort.
Patients who had a poor response to TKI therapy and had a HSCT had worse outcomes
compared to those who received TKI mono-therapy. Although patients that underwent HSCT
after TKI therapy were a more heterogeneous group in terms of disease status at time of
HSCT (with some patients having more aggressive disease features than patients receiving
TKI monotherapy), the three deaths in the HSCT group in the TKI era were all related to
transplant complications. One patient who received dasatinib after imatinib failure
(secondary to family preference) is alive and in remission. Given that no death was attributed
to the primary disease process, the effectiveness of HSCT at eradicating CML is not
debated. However the increased mortality associated with this treatment suggests further
advances in HSCT may be required to outweigh the benefits of a TKI mono-therapy
approach in the vast majority of childhood CML patients.

There are three key limitations of this study. First, our population cohort captured patients
cared for in the pediatric system. It is likely that there were adolescent patients diagnosed in
this period that were cared for in adult oncology programs and are not included in this
analysis. For this reason, we are unable to report or comment on the incidence of childhood
CML over time. Second, data captured did not include several potentially important
elements including information on medication compliance, discontinuation of TKI therapy
and laboratory data on mutation screening for TKI resistance. Third, each institution had a
different method of managing medical data, with only two institutions maintaining electronic
heath records; there were incidents when specific data was missing from paper charts and
not available for extraction (symptoms at diagnosis were not reported/available in five
This article is protected by copyright. All rights reserved.
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patients).

In conclusion, TKI therapy is a safe, effective treatment for childhood CML that has
decreased mortality in children with this disease. In our cohort, no patient treated with a TKI
died of progressive disease and all patients died related to HSCT complications. While
HSCT is recommended for patients with particularly aggressive features, our results suggest
further advancements in outcomes for children with CML will require either improvement in
HSCT and/or optimization of medical therapy that overcomes the need for HSCT. For
patients with primary refractory disease, or those who progress on TKI therapy, our data
supports the current recommendations to switch to an alternative second generation TKI
with HSCT delayed where possible. HSCT should be reserved for patients with blast phase
disease, particularly those that evolve while on TKI therapy.
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TABLE 1

Clinical features of entire cohort at diagnosis (n = 52)
Age at diagnosis (years), median
10.5 (1.8-18)
(range)
Male: Female
29:23 (56%: 44%)
Symptoms at diagnosis* %:
Bone pain
28%
Fatigue
28%
Abdominal pain
21%
Abdominal fullness
21%
Fever
17%
Weight loss
17%
Bruising
13%
Retinal hemorrhage
2%
Blurred vision
2%
Ankle swelling
2%
Priapism
2%
Skin lesion
2%
Asymptomatic
17%
Splenomegaly identified on exam
72%
WCC, median (range)
241 (25-683)
Hgb, median (range)
88 (37-170)
Platelets, median (range)
536 (13-2178)
Stage at diagnosis (%):
Chronic phase
46 (88%)
Accelerated phase
1 (2%)
Blast phase
5 (10%)

*Data was available regarding symptoms at diagnosis in 47 patients

This article is protected by copyright. All rights reserved.

14

TABLE 2
Characteristics of patients treated in the TKI era
(n = 30)
TKI used upfront:
Imatinib

23

Dasatinib

4

No TKI used

3

Dose of Imatinib (mg/m2) median (range)

300 (260-340)

Reason for discontinuing initial TKI:
Elective transplant in CP (2002-2005)

2

Poor disease response*

8

Intolerance (GI upset, joint effusion)

2

Received HSCT

12

Donor Source
Matched sib donor

5

Matched unrelated donor

7

Overall survival (%)
HSCT after TKI use

6/9 (66%)

HSCT with no TKI use

3/3 (100%)

Imatinib monotherapy first-line

13/13 (100%)

Dasatinib monotherapy first-line

2/2 (100%)

Switch from imatinib to dasatinib

3/3 (100%)

* 3 patients developed blasts crisis, 3 patients failed to achieve cytogenetic remission, 1
patient developed resistance to TKI therapy, 1 patient presented with BC at diagnosis
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